Polypharmacy Among People Living with Dementia — Israel and 24 Countries in European Union, 2015–2019  

作　　者：Shanquan Chen Xi Chen Huanyu Zhang 

机构地区：[1]Department of Psychiatry,University of Cambridge,Cambridge,United Kingdom [2]School of Public Health,Yale University,New Haven,Connecticut,United States [3]Shenzhen Research Institute,the Chinese University of Hong Kong,Shenzhen,China.

出　　处：《China CDC weekly》2022年第45期1007-1012,共6页中国疾病预防控制中心周报（英文）

摘　　要：What is already known about this topic?With a growing number of people living with dementia(PLWD),the practice of taking multiple medications to manage symptoms or comorbidities,i.e.,polypharmacy,among PLWD has become a global health challenge.What is added by this report?In 2015–2019,polypharmacy for PLWD varied substantially among 25 studied countries,with approximately 1 in 5 Estonian PLWD and 4 in 5 Cypriot PLWD having polypharmacy.In addition,Switzerland,Poland,Austria,and the Czech Republic have experienced a significantly increasing trend in polypharmacy for PLWD.What are the implications for public health practice?Countries should pay special attention to polypharmacy and make efforts to control polypharmacy among PLWD,especially in countries where the trend of polypharmacy among PLWD has been increasing.

关 键 词：MEDICATION Israel PHARMACY 

分 类 号：R749.16[医药卫生—神经病学与精神病学]